GRx+Biosims 2020 is going virtual!
The mission of providing America’s patients with access to the generic and biosimilar medicines they need remains our top priority. As this country faces the challenges of COVID-19, the importance of our mission comes into clearer focus – and the need to share knowledge and best practices has even greater urgency.
Due to public health and safety concerns related to the coronavirus (COVID-19) pandemic, we decided to web-stream the conference. The format may be new but will still allow you to participate in Q&A with speakers, engage with your peers and meet with exhibitors.
Virtual Networking Experience
AAM will host a variety of exciting professional networking opportunities during the virtual conference. There will be easy ways to find people in the online setting rather than hoping you’ll run into them in a vast conference space.
Sponsorship Opportunities
To make this the best experience possible for your organization, with lasting results, we’ve shaped packages that will give you sustained visibility and create connections during the event. All packages have been enhanced with digital marketing benefits that promote your products and services to the registered attendees. For more information regarding sponsorship levels and benefits contact Jennifer Soup at jennifer.soup@accessiblemeds.org.
Exposition
Each year, we gather dozens of exhibitors who offer a highly interactive and professional business environment in which industry vendors can meet generics and biosimilars industry executives. You still have the opportunity to connect with providers covering every aspect of the industry. These vendors are eager to share their industry know-how and keep you up to date on the latest health care industry trends. The virtual exhibit hall will give you the opportunity to engage in private and public chats, download materials, view videos and so much more.
2019 Social Media Highlights — #GRxBiosims
View Facebook Photo Album
View Tweet
|
View Tweet
|
View Tweet
|
View Tweet | View Tweet | View Tweet |